Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that it will present new clinical data from the ongoing Phase II portion of its COVALENT-111 trial, which is evaluating BMF-219 as a treatment for patients with type 2 diabetes, in a late-breaking poster presentation at the 2023 American Diabetes Association (ADA) 83rd Scientific Sessions, to be held June 23 – 26, 2023 in San Diego, CA. The company will also host an investor and KOL event during the Scientific Session.
Biomea will disclose additional information about the late-breaking presentation in accordance with ADA’s abstract embargo policies. In addition, the company will provide further details on the investor and KOL event at a later date.
https://finance.yahoo.com/news/biomea-fusion-present-breaking-data-123000411.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.